Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Swiss National Bank

Swiss National Bank boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 0.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,788,600 shares of the medical research company's stock after purchasing an additional 8,300 shares during the quarter. Swiss National Bank owned about 0.30% of Edwards Lifesciences worth $118,030,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Park Avenue Securities LLC boosted its holdings in Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company's stock valued at $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank lifted its position in shares of Edwards Lifesciences by 16.5% in the second quarter. City State Bank now owns 917 shares of the medical research company's stock valued at $85,000 after acquiring an additional 130 shares in the last quarter. Stableford Capital II LLC grew its holdings in shares of Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company's stock worth $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC raised its holdings in Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company's stock valued at $297,000 after acquiring an additional 160 shares during the last quarter. Finally, Busey Bank increased its holdings in shares of Edwards Lifesciences by 1.9% in the second quarter. Busey Bank now owns 8,838 shares of the medical research company's stock valued at $816,000 after purchasing an additional 165 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on EW. Daiwa Capital Markets raised shares of Edwards Lifesciences from a "neutral" rating to an "outperform" rating in a research note on Wednesday, July 31st. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 28th. Baird R W cut shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 25th. Evercore ISI decreased their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st. Finally, Barclays dropped their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $75.67.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock valued at $2,657,000 over the last three months. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 0.4 %

Edwards Lifesciences stock traded up $0.25 during trading on Tuesday, hitting $70.14. The company's stock had a trading volume of 2,620,370 shares, compared to its average volume of 4,644,555. The stock has a market capitalization of $41.37 billion, a price-to-earnings ratio of 9.88, a P/E/G ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's fifty day moving average is $67.53 and its 200 day moving average is $76.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. The firm's quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.